We scan new podcasts and send you the top 5 insights daily.
Fizazi notes PSMAfore improved radiographic progression-free survival with a hazard ratio of 0.5, yet showed no overall survival benefit because most control patients crossed over to lutetium PSMA, often progressing within six months. He frames the comparison as immediate versus deferred radioligand therapy. Quality-of-life and symptomatic progression still favored treatment.
The trial allowed patients in the placebo group to receive retifanlimab upon progression (crossover). This common design dilutes the observed overall survival difference. While initial results were not statistically significant, updated data revealed a clinically meaningful 10.6-month median OS improvement.
In metastatic hormone-sensitive prostate cancer, many patients receive multiple subsequent therapies, making Overall Survival (OS) a difficult endpoint to achieve. Therefore, a large, meaningful improvement in radiographic progression-free survival (RPFS) is considered a critical and actionable outcome for patients.
In trials like ASCENT-4, where over 80% of the control arm received sacituzumab govitecan upon progression, the true overall survival (OS) benefit is obscured. This makes progression-free survival (PFS) a more reliable endpoint for evaluating the drug's first-line efficacy.
In pivotal ADC trials like ASCENT-03 and 04, over 80% of patients in the control (chemotherapy) arm received the ADC upon progression. This high crossover rate makes interpreting overall survival (OS) data difficult, as the control group's outcomes are artificially improved by subsequent access to the novel drug.
The common practice of switching from one ARPI to another upon disease progression is now considered ineffective for most patients. With the advent of proven alternatives like chemotherapy and lutetium, using an "ARPI switch" as the sole control arm in clinical trials is no longer ethically or scientifically sound.
In metastatic hormone-sensitive prostate cancer (mHSPC), radiographic progression-free survival (rPFS) is no longer seen as a convincing primary endpoint on its own. Clinicians demand a clear signal for overall survival (OS) improvement, citing historical data where early treatment intensification showed significant OS gains.
An expert expressed disappointment with Lutetium's efficacy in the metastatic hormone-sensitive setting, suggesting its benefit is lower than expected. A potential flaw in trial design was starting hormonal agents first, which can lower PSMA expression, thereby potentially reducing the radioligand's target and diminishing its therapeutic effect.
ASCENT-03 did not demonstrate early overall survival separation because 80% of control patients crossed over to sacituzumab upon disease progression. In contrast, Tropion Breast-02 prohibited structured crossover, allowing datopotamab deruxtecan to demonstrate statistically significant improvements across both progression-free and overall survival endpoints.
Expert analysis reveals a key weakness in many Lutetium-PSMA trials: the choice of the control arm. By comparing the novel therapy against a less-than-optimal standard of care, the trials may have been designed for an "easy win," dampening expert enthusiasm and raising questions about its true superiority over other potent hormonal therapies.
The endpoint of radiographic progression-free survival (rPFS) is heavily criticized as not being clinically meaningful. The intensive scanning schedule required in trials (e.g., every 8-12 weeks regardless of symptoms) is never replicated in standard clinical practice, making it an artificial measure of patient benefit.